Advertisement

GH

Guardant Health, Inc.

Healthcare · USD

Set alert

Price alert · GH

All alert types
178.80 USD -6.51 -3.51%
As of Oct 30, 2026 Extended hours 178.90 +0.06%
Bid
178.78 × 2
Ask
178.82 × 2
175.44 Day range 185.65
78.60 52-week range 187.22
YTD
+75.05%
1 year
+93.49%
Open
182.48
Prev close
185.31
Mkt cap
23.99B
Vol
1.50M
Avg vol
1.94M
EPS
-3.50
P/E
0.00
Div yield
0.00%
More statistics
Low
175.44
High
185.65
Forward P/E
-471.56
Beta
1.58
Short ratio
6.12
Inst. own
100.98%
Dividend
0.00
Ex-div date
Earnings
Nov 5, 2026
50-d avg
169.49
200-d avg
130.15
1y target
202.24

5D chart

Chart tools
Interval
GH five-day price chart168.7173.1177.4181.7186.0Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
23.99B
Enterprise value
25.51B
Trailing P/E
0.00
Forward P/E
-471.56
PEG ratio
0.00
Price / sales
20.28
Price / book
0.00
EPS (TTM)
-3.50
Beta
1.58
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-38.33%
Revenue (TTM)
1.18B
Revenue growth
44.30%
Free cash flow
26.61M
Total cash
1.05B
Total debt
1.70B
Return on equity
0.00%
Shares outstanding
134.20M
Short % of float
9.06%
50-day average
169.49
200-day average
130.15

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 202.24 +13.1% upside
Target (low)
105.00
Target (mean)
202.24
Target (high)
240.00
Ratings (0m) 26 25 buy · 0 hold · 1 sell
  • Strong buy4
  • Buy21
  • Hold0
  • Sell0
  • Strong sell1

Next earnings

Nov 5, 2026

Expected Nov 5, 2026. Consensus EPS estimate -0.31444.

Earnings history

Financials — quick view

All financials
GH Revenue — quarterly 334.98M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
GH Net income — quarterly -120.14M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
GH EPS — quarterly -0.90
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

GH recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 2026-0.75———
Jul 30, 2026Jun 30, 2026-0.76183-0.90-0.14-18.14%
May 7, 2026Mar 31, 2026-0.806-0.85-0.04-5.46%
Feb 19, 2026Dec 31, 2025-0.76677-1.00-0.23-30.42%
Oct 29, 2025Sep 30, 2025-0.78962-0.74+0.05+6.28%
Jul 30, 2025Jun 30, 2025-0.74051-0.80-0.06-8.03%

Upgrades / downgrades

GH analyst upgrades and downgrades
DateFirmActionFromTo
Oct 27, 2026BTIGmainBuyBuy
Oct 23, 2026Roth Capitalinit—Buy
Oct 13, 2026Morgan StanleymainOverweightOverweight
Oct 7, 2026BarclaysmainOverweightOverweight
Oct 1, 2026GuggenheimmainBuyBuy
Sep 9, 2026UBSmainBuyBuy

About Guardant Health, Inc.

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States

News

Your note

Sign in to keep a note on GH — it syncs with the Stock Master app.

Insider holders

GH insider holders
InsiderRelationLatest transactionDateShares held
BELL MICHAEL BRIANChief Financial OfficerConversion of Exercise of derivative securityJun 30, 202651,816
CHUDOVA DARYAChief Technology OfficerSaleSep 14, 202670,635
EAGLE CRAIGOfficerConversion of Exercise of derivative securityMar 31, 202672,001
ELTOUKHY HELMY AChief Executive OfficerStock GiftAug 25, 20260
FREEMAN CHRISOfficerConversion of Exercise of derivative securityAug 9, 202665,374
GADDE VIJAYA V.DirectorConversion of Exercise of derivative securityJun 16, 202628,517

Institution ownership

GH institution ownership
Holder% heldSharesValueReported
Blackrock Inc.5.68%7,622,9351.36BJun 29, 2026
Price (T.Rowe) Associates Inc4.85%6,514,9521.16BJun 29, 2026
Vanguard Capital Management LLC4.29%5,755,8571.03BJun 29, 2026
FMR, LLC4.09%5,488,272981.30MJun 29, 2026
Vanguard Portfolio Management LLC4.06%5,445,785973.71MJun 29, 2026
Invesco Ltd.3.30%4,429,755792.04MJun 29, 2026

Fund ownership

GH fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.98%3,999,645715.14MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.15%2,888,524516.47MJun 29, 2026
T. Rowe Price New Horizons Fund, Inc.1.33%1,778,489317.99MJun 29, 2026
Franklin Custodian Funds-FRANKLIN DYNATECH FUND1.30%1,750,000312.90MJun 29, 2026
Capitol Series Trust-FullerThaler Behavioral Small-Cap Growth Fund1.29%1,729,500309.23MJun 29, 2026
VANGUARD WORLD FUND-Vanguard U.S. Growth Fund1.28%1,716,540306.92MMay 30, 2026
Advertisement